This study demonstrated that the nuclear PLSCR1 facilitates the PLSCR1-IP3R1-Ca2+ pathway leading to the differentiation of primary AML cells (Figure 7), which is responsible for wogonoside-induced anti-leukemia activity, suggesting the potential of developing of wogonoside into a novel agent for the AML treatment. This evidence concerns the gene PLSCR1 and leukemia.